Peerschke E - Search Results

1

gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma.

Peerschke E, Stier K, Li X, Kandov E, de Stanchina E, Chang Q, Xiong Y, Manova-Todorova K, Fan N, Barlas A, Ghebrehiwet B, Adusumilli PS. Peerschke E, et al. Front Oncol. 2020 Aug 12;10:1413. doi: 10.3389/fonc.2020.01413. eCollection 2020. Front Oncol. 2020. PMID: 32903438 Free PMC article.

2

Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer.

Peerschke EI, Stanchina E, Chang Q, Manova-Todorova K, Barlas A, Savitt AG, Geisbrecht BV, Ghebrehiwet B. Peerschke EI, et al. Antibodies (Basel). 2020 Oct 6;9(4):51. doi: 10.3390/antib9040051. Antibodies (Basel). 2020. PMID: 33036212 Free PMC article.

3

Heterozygous P32/C1QBP/HABP1 Polymorphism rs56014026 Reduces Mitochondrial Oxidative Phosphorylation and Is Expressed in Low-grade Colorectal Carcinomas.

Raschdorf A, Sünderhauf A, Skibbe K, Ghebrehiwet B, Peerschke EI, Sina C, Derer S. Raschdorf A, et al. Among authors: peerschke ei. Front Oncol. 2021 Feb 8;10:631592. doi: 10.3389/fonc.2020.631592. eCollection 2020. Front Oncol. 2021. PMID: 33628739 Free PMC article.

4

Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.

Li X, Eguchi T, Aly RG, Chintala NK, Tan KS, Zauderer MG, Dembitzer FR, Beasley MB, Ghebrehiwet B, Adusumilli PS, Peerschke EIB. Li X, et al. Front Oncol. 2019 Oct 11;9:1042. doi: 10.3389/fonc.2019.01042. eCollection 2019. Front Oncol. 2019. PMID: 31681580 Free PMC article.

5

Complement and coagulation: key triggers of COVID-19-induced multiorgan pathology.

Ghebrehiwet B, Peerschke EI. Ghebrehiwet B, et al. J Clin Invest. 2020 Nov 2;130(11):5674-5676. doi: 10.1172/JCI142780. J Clin Invest. 2020. PMID: 32925166 Free PMC article. Review.

6

SLE: Novel Postulates for Therapeutic Options.

Hosszu KK, Valentino A, Peerschke EI, Ghebrehiwet B. Hosszu KK, et al. Front Immunol. 2020 Oct 7;11:583853. doi: 10.3389/fimmu.2020.583853. eCollection 2020. Front Immunol. 2020. PMID: 33117397 Free PMC article. Review.

7

Monocyte Expressed Macromolecular C1 and C1q Receptors as Molecular Sensors of Danger: Implications in SLE.

Ghebrehiwet B, Hosszu KK, Valentino A, Ji Y, Peerschke EI. Ghebrehiwet B, et al. Front Immunol. 2014 Jun 26;5:278. doi: 10.3389/fimmu.2014.00278. eCollection 2014. Front Immunol. 2014. PMID: 25018754 Free PMC article. Review.

8

cC1qR/CR and gC1qR/p33: observations in cancer.

Peerschke EI, Ghebrehiwet B. Peerschke EI, et al. Mol Immunol. 2014 Oct;61(2):100-9. doi: 10.1016/j.molimm.2014.06.011. Epub 2014 Jul 16. Mol Immunol. 2014. PMID: 25044096 Review.

9

Is the A-Chain the Engine That Drives the Diversity of C1q Functions? Revisiting Its Unique Structure.

Ghebrehiwet B, Kandov E, Kishore U, Peerschke EIB. Ghebrehiwet B, et al. Among authors: peerschke eib. Front Immunol. 2018 Feb 5;9:162. doi: 10.3389/fimmu.2018.00162. eCollection 2018. Front Immunol. 2018. PMID: 29459870 Free PMC article.

10

The C1q Receptors: Focus on gC1qR/p33 (C1qBP, p32, HABP-1)¹.

Ghebrehiwet B, Geisbrecht BV, Xu X, Savitt AG, Peerschke EIB. Ghebrehiwet B, et al. Semin Immunol. 2019 Oct;45:101338. doi: 10.1016/j.smim.2019.101338. Epub 2019 Nov 16. Semin Immunol. 2019. PMID: 31744753 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

175 results

Search Page